RISK MANAGEMENT PLAN
For
Palbociclib Viatris (Palbociclib)
Version 0.2

RMP Version to be Assessed as Part of this Application:

RMP Version Number	0.2
Data Lock Point for this RMP	27-Feb-2025
Date of Final Sign Off	11-Dec-2025
Rationale for Submitting an Updated RMP	RMP amended in line with the Day 80 critical assessment report (AR), dated 11-Aug-2025, and Day 120 CHMP list of questions (LOQ), dated 18-Sep-2025, for palbociclib procedure number EMEA/H/C/6624.
Summary of Significant Changes in this RMP	The following significant changes were made during the current RMP: • Part V update: Removed table 4 and table 5 and indicated modules V.1, V.2, and V.3 as "Not applicable."

Other RMP Versions Under Evaluation:

RMP Version Number	0.1
Submitted On	05-May-2025
Procedure Number	EMEA/H/C/6624

Details of the Current RMP:

Version Number	Not applicable
Approved with Procedure	Not applicable
Date of Approval (Opinion Date)	Not applicable

QPPV: Dr Eiko Soehlke, MD MPH, EEA QPPV

QPPV oversight declaration: The content of this RMP has been reviewed and approved by the marketing authorisation applicant´s QPPV. The electronic signature is available on file.

Table of Contents

LIST OF TABLES

LIST OF ABBREVIATIONS

Abbreviation	Definition
ADR	Adverse Drug Reaction
ATC	Anatomical Therapeutic Chemical Classification System
CHMP	Committee for Medicinal Products for Human Use
CMDh	Coordination Group for Mutual Recognition and Decentralised Procedures – Human
DCP	Decentralised Procedure
DDD	Daily Defined Dose
DHPC	Direct Healthcare Professional Communication
EEA	European Economic Area
EPAR	European Public Assessment Report
EU	European Union
EURD	European Union Reference Date
HCP	Healthcare Professional
ICSR	Individual Case Safety Report
MAA	Marketing Authorization Applicant
MAH	Marketing Authorization Holder
MRP	Mutual Recognition Procedure
PAC	Patient Alert Card
PL	Package Leaflet
PPP	Pregnancy Prevention Programme
PRAC	Pharmacovigilance Risk Assessment Committee
PSUR	Periodic Safety Update Report
PTC	Patient Treatment Course
PTD	Patient Treatment Days
PTM	Patient Treatment Months
PTY	Patient Treatment Years
PVA	Pharmacovigilance Agreement
QPPV	Qualified Person for Pharmacovigilance
MedDRA	Medical Dictionary for Regulatory Activities
DLP	Data Lock Point
SmPC	Summary of Product Characteristics
WHO	World Health Organization

PART I: PRODUCT(S) OVERVIEW

Table 1: Part 1.1-Product Overview

Active Substance(s) (INN or Common Name)	Palbociclib
Pharmacotherapeutic Group(s) (ATC Code)	Antineoplastic agents, protein kinase inhibitors, ATC code: L01EF01
Marketing Authorisation Applicant	Viatris Limited.
Medicinal Products to Which this RMP Refers	01
Invented Name(s) in the European Economic Area (EEA)/UK	Palbociclib Viatris 75 mg film coated tablets Palbociclib Viatris 100 mg film coated tablets Palbociclib Viatris 125 mg film coated tablets
Marketing Authorisation Procedure	Centralised (EMEA/H/C/0006624)
Brief Description of the Product	Chemical class Palbociclib is a highly selective, reversible, small molecule inhibitor of CDK 4 and 6. The chemical name of the palbociclib free base is 6-acetyl-8-cyclopentyl-5- methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin- 7(8H)-one. Summary of mode of action Palbociclib is a highly selective, reversible inhibitor of cyclin dependent kinases (CDK) 4 and 6. Cyclin D1 and CDK4/6 are downstream of multiple signaling pathways which lead to cellular proliferation. Important information about its composition Not applicable
Hyperlink to the Product Information:	PI available in section 1.3.1 of the dossier
Indication(s) in the EEA/UK	Current: Palbociclib Viatris is indicated for the treatment of: Hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer. -in combination with an aromatase inhibitor; -in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

	Proposed: Not applicable
Dosage in the EEA/UK	Current: The recommended dose is 125 mg of palbociclib once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. When co-administered with palbociclib, the aromatase inhibitor should be administered according to the dose schedule reported in the Summary of Product Characteristics. Treatment of pre/perimenopausal women with the combination of palbociclib plus an aromatase inhibitor should always be combined with an LHRH agonist. (kindly refer SmPC for more details) When coadministered with palbociclib, the recommended dose of fulvestrant is 500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter. Prior to the start of treatment with the combination of palbociclib plus fulvestrant, and throughout its duration, pre/perimenopausal women should be treated with LHRH agonists according to local clinical practice. Patients should be encouraged to take their dose at approximately the same time each day. If the patient vomits or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time. Proposed: Not applicable
Pharmaceutical Form(s) and Strengths	Current: 75, 100, 125 mg film-coated tablets Proposed: Not applicable
Is/Will the Product Be Subject to Additional Monitoring in the EU/UK?	No

PART II: SAFETY SPECIFICATION

Part II: Module SI - Epidemiology of the Indication(s) and Target Population(s)

Not applicable.

Part II: Module SII - Non-clinical Part of the Safety Specification

Not applicable.

Part II: Module SIII - Clinical Trial Exposure

Not applicable.

Part II: Module SIV - Populations Not Studied in Clinical Trials

SIV.1 Exclusion Criteria in Pivotal Clinical Studies Within the Development Programme

Not applicable.

SIV.2 Limitations to Detect Adverse Reactions in Clinical Trial Development Programmes

Not applicable.

SIV.3 Limitations in Respect to Populations Typically Under-represented in Clinical Trial Development Programmes

Not applicable.

Part II: Module SV - Post-authorisation Experience

Not applicable.

Part II: Module SVI - Additional EU/UK Requirements for the Safety Specification

Not applicable.

Part II: Module SVII - Identified and Potential Risks

SVII.1 Identification of Safety Concerns in the Initial RMP Submission

This is a MAA for a generic medicine in which the safety concerns available in the RMP for the reference medicinal product have been adopted by the applicant (Ibrance® 75, 100 and 125 mg film coated tablets from Pfizer Europe MA EEIG).

Table 2: SVII- Summary of safety concerns

Summary of Safety Concerns	
Important Identified Risks	None
Important Potential Risks	Reproductive and Developmental Toxicity
Missing Information	None

SVII.1.1. Risks Not Considered Important for Inclusion in the List of Safety Concerns in the RMP

Not applicable as all risks from reference product RMP have been considered in this RMP.

SVII.1.2. Risks Considered Important for Inclusion in the List of Safety Concerns in the RMP

Not applicable as all risks from reference product RMP have been considered in this RMP.

SVII.2 New Safety Concerns and Reclassification with a Submission of an Updated RMP

Not applicable as this is the initial RMP for palbociclib.

SVII.3 Details of Important Identified Risks, Important Potential Risks, and Missing Information

SVII.3.1. Presentation of Important Identified Risks and Important Potential Risks

Not applicable as this RMP for palbociclib follows the same safety concerns as the safety concerns of the reference substance RMP.

SVII.3.2. Presentation of the Missing Information

Not applicable as this RMP for palbociclib follows the same safety concerns as the safety concerns of the reference substance RMP.

Part II: Module SVIII - Summary of the Safety Concerns

Table 3: SVIII- Summary of safety concerns

Summary of Safety Concerns	
Important Identified Risks	None
Important Potential Risks	Reproductive and Developmental Toxicity
Missing Information	None

PART III: PHARMACOVIGILANCE PLAN (INCLUDING POST-AUTHORISATION SAFETY STUDIES)

The Pharmacovigilance System Master File contains details of the system and processes that the Applicant has in place to identify and/or characterize the risks recognised in the safety specification.

III.1 Routine Pharmacovigilance Activities

Routine pharmacovigilance activities only.

III.2 Additional Pharmacovigilance Activities

As current routine pharmacovigilance activities are sufficient, no additional pharmacovigilance activities are recommended.

III.3 Summary Table of Additional Pharmacovigilance Activities

Not applicable.

PART IV: PLANS FOR POST-AUTHORISATION EFFICACY STUDIES

Not applicable.

PART V: RISK MINIMISATION MEASURES ((INCLUDING EVALUATION OF THE EFFECTIVENESS OF RISK MINIMISATION ACTIVITIES))

Risk Minimisation Plan

The safety information in the proposed product information is aligned to the reference medicinal product (*Ibrance*®, MAH: Pfizer Europe MA EEIG).

V.1 Routine Risk Minimisation Measures

Not applicable.

V.2 Additional Risk Minimisation Measures

Not applicable.

V.3 Summary of Risk minimisation measures

Not applicable.

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of Risk Management Plan for Palbociclib Viatris (Palbociclib)

This is a summary of the risk management plan (RMP) for Palbociclib Viatris. The RMP details important risks of Palbociclib Viatris, how these risks can be minimised, and how more information will be obtained about Palbociclib Viatris's risks and uncertainties (missing information).

Palbociclib Viatris's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Palbociclib Viatris should be used.

This summary of the RMP for Palbociclib Viatris should be read in the context of all the information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Palbociclib Viatris's RMP.

I. The Medicine and What it is Used For

Palbociclib Viatris is authorised for the treatment of :

Hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer

- in combination with an aromatase inhibitor.
- in combination with fulvestrant in women who have received prior endocrine therapy.

Pre or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist (see SmPC for the full indication).

It contains palbociclib as the active substance and it is given by oral route of administration.

Further information about the evaluation of Palbociclib Viatris's benefits can be found in Palbociclib Viatris's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage.

II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks

Important risks of Palbociclib Viatris together with measures to minimise such risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific Information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimises its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of Important Risks and Missing Information

Important risks of Palbociclib Viatris are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken by patients. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Palbociclib Viatris. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine/use in special patient populations etc.);

Table 4: Part VI.1- Summary of safety concerns

List of Important Risks and Missing Information	
Important Identified Risks	None
Important Potential Risks	Reproductive and Developmental Toxicity
Missing Information	None

II.B Summary of Important Risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-Authorisation Development Plan

II.C.1 Studies Which are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Palbociclib Viatris.

II.C.2 Other Studies in Post-Authorisation Development Plan

There are no studies required for Palbociclib Viatris.